37 results
8-K
EX-99.1
NTLA
Intellia Therapeutics Inc
15 Apr 24
Departure of Directors or Certain Officers
4:21pm
, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration, the Innovation Passport by the U.K. Medicines and Healthcare products
8-K
EX-99.1
NTLA
Intellia Therapeutics Inc
1 Feb 24
Regulation FD Disclosure
4:05pm
, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration, the Innovation Passport by the U.K. Medicines and Healthcare products
8-K
EX-99.1
h8f4bz69yholqn
4 Jan 24
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones
4:07pm
8-K
74s5e9 lm
4 Jan 24
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones
4:07pm
8-K
EX-99.1
4ued6y9 511tvr
9 Nov 23
Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
7:45am
8-K
EX-99.1
hn0cb0m ar
3 Aug 23
Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
7:45am
8-K
EX-99.1
u0nc6yeietmdjg dvokh
4 May 23
Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
7:41am
PRE 14A
tfdc0 hzvaeb9rwx
18 Apr 23
Preliminary proxy
4:16pm
8-K
EX-99.1
rpqoywx gmcpis2cw1
5 May 22
Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress
7:40am